(Q79186235)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

relapsing-remitting multiple sclerosis

1 reference

inferred from title

author

Per Soelberg Sørensen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Thor Petersen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Egon Stenager

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Christian Ross

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Katja Maria Clemmesen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Klaus Bendtzen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Jette Lautrup Frederiksen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Kai Jensen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ole Kristensen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Soren Rasmussen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Mads Ravnborg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Nils Koch-Henriksen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Danish Multiple Sclerosis Study Group

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

1184-1191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

9391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

A sensitive antiviral neutralization bioassay for measuring antibodies to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914541-2

7 January 2021

10.1016/S0140-6736(03)14541-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568740%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference